Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25587030
Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27 25587030
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T37-p - 4E-BP1 (human)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 no change compared to control
rapamycin no change compared to control
U0126 no change compared to control
Torin1 decrease

T46-p - 4E-BP1 (human)
Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 no change compared to control
rapamycin no change compared to control
U0126 no change compared to control
Torin1 decrease

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester no change compared to control
Torin1 decrease
U0126 decrease

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in 10% FBS, slight induction without FBS
rapamycin no change compared to control
U0126 no change compared to control
Torin1 no change compared to control

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in 10% FBS, slight induction without FBS
rapamycin no change compared to control
U0126 no change compared to control
Torin1 no change compared to control

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in 10% FBS, slight induction without FBS
rapamycin no change compared to control
U0126 no change compared to control
Torin1 no change compared to control

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in 10% FBS, slight induction without FBS
rapamycin no change compared to control
U0126 no change compared to control
Torin1 no change compared to control

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 decrease
rapamycin decrease
Torin1 decrease

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 decrease

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 decrease

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in presence and absense of 10% serum
U0126 decrease
rapamycin decrease
Torin1 decrease

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in presence and absense of 10% serum
U0126 decrease
rapamycin decrease
Torin1 decrease

S240-p - S6 (human)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in presence and absense of 10% serum
U0126 no change compared to control
rapamycin decrease
Torin1 decrease

S244-p - S6 (human)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase in presence and absense of 10% serum
U0126 no change compared to control
rapamycin decrease
Torin1 decrease